Laboratório de Bacteriologia Aplicada, Departamento de Medicina Veterinária Preventiva, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Vaccine. 2013 Oct 1;31(42):4856-9. doi: 10.1016/j.vaccine.2013.07.063. Epub 2013 Aug 7.
The aims of the present study were (i) to assess the in vitro genetic stability of S19 and RB51 Brucella abortus vaccines strains and (ii) to evaluate the ability of multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA) as a tool to be used in the quality control of live vaccines against brucellosis. Sixty-three batches of commercial S19 (n=53) and RB51 (n=10) vaccines, produced between 2006 and 2009, were used in this study. S19 and RB51 vaccines were obtained from, respectively, seven and two different manufacturers. Ten in vitro serial passages were performed on reference strains and on selected batches of commercial vaccines. All batches, reference strains and strains of serial passages were typed by the MLVA16. The results demonstrated that B. abortus S19 and RB51 vaccine strains are genetically stable and very homogeneous in their respective groups. Anyway, batches of S19 from one manufacturer and batches of RB51 from another presented genotypes distincts from the reference vaccine strains. In both cases, differences were found on locus Bruce07, which had addition of one repeat unit in the case of S19 batches and the deletion of one repeat unit in the case of RB51 batches. In summary, MLVA16 proved to be a molecular tool capable of discriminating small genomic variations and should be included in in vitro official tests.
(i)评估 S19 和 RB51 布氏流产疫苗株的体外遗传稳定性;(ii)评估多位点可变数目串联重复分析(MLVA)作为一种工具,用于布鲁氏菌病活疫苗的质量控制。本研究使用了 63 批商业 S19(n=53)和 RB51(n=10)疫苗,生产于 2006 年至 2009 年之间。S19 和 RB51 疫苗分别来自 7 个和 2 个不同的制造商。对参考株和选定的商业疫苗批次进行了 10 次体外连续传代。所有批次、参考株和传代株均通过 MLVA16 进行分型。结果表明,B. abortus S19 和 RB51 疫苗株在各自的群体中具有遗传稳定性和高度同源性。然而,来自同一制造商的 S19 批次和来自另一家制造商的 RB51 批次的疫苗具有与参考疫苗株不同的基因型。在这两种情况下,都发现了 Bruce07 基因座的差异,S19 批次的重复单元增加了一个,而 RB51 批次的重复单元减少了一个。总之,MLVA16 被证明是一种能够区分小基因组变异的分子工具,应纳入体外官方测试。